Tumour markers are proteins found in the blood, tissue or urine that may be directly produced by a tumour or by other tissues in response to the presence of a tumour.
Prostate cancer is the second most common cause of cancer in men. If it is detected early enough, it has a 90% cure rate. Carcinoembryonic Antigen (CEA), a non-specific cancer antigen produced in response to malignant cells, is measured in addition to total and free Prostate Specific Antigen (PSA). Therefore, testing for CEA simultaneously with PSA provides a more accurate diagnosis of prostate cancer. Randox Tumour PSA Array enables the simultaneous determination of these antigens in a single sample.
Tumour PSA Array
- Free Prostate Specific Antigen (fPSA)
- Total Prostate Specific Antigen (tPSA)
- Carcinoembryonic Antigen (CEA)
Benefits of the Randox Tumour PSA Array
- Multiplex testing from a single sample
- Suitable for human serum samples
- Small sample volume
- Excellent analytical performance
- Fast throughput
- Applicable to both fully automated and semi-automated Evidence analysers